hepatology

The second prize is a five-year $ 14.

The second prize is a five-year $ 14,000 contract with the National Institute of Diabetes and Digestive and Kidney Diseases . This contract funds cellular and molecular biology laboratory to services and infrastructure in support of research in the search for the causes of metabolic and digestive diseases. Resources such ase Professor David Toke is the NIDDK project manager.

The first prize is a five-year cooperative agreement with the National Institute of Mental Health, for Genomic Studies on Mental Disorders at Rutgers. It has received a budget of $ 42,000 and an additional award of $ 1,000 in September. Continue reading

Are confident that far above those required for adequate receptor blockade.

‘.. The results of the study showed that CCX354 was well tolerated and showed a linear dose – risk profile in single-dose and multiple-dose Phase I studies in healthy volunteers. Are confident that far above those required for adequate receptor blockade. High levels of receptor coverage at the 12-hour time point were achieved after a single dose of 100 mg of CCX354. – ‘Our data and the reports of other labs now show that the importance of a high degree of CCR1 receptor coverage to achieve a therapeutic effect in inflammatory diseases such as RA,’said Thomas J. President and Chief Executive Officer of ChemoCentryx. ‘We are extremely pleased that this study demonstrated the unique ability of CCX354, selectively and sufficiently block the CCR1 receptor ssobjectives that other molecules in this class failed to achieve to date.

CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor, the recruitment of inflammatory monocytes and macrophages in the drives joints of patients with RA. By selectively blocking the CCR1 receptor is designed CCX354, Although of inflammatory cells in the joints of patients to decrease rheumatoid arthritis and inhibition of inflammation, swelling, pain and associated joint destruction while minimizing the potential for off-target effects, thus a wider therapeutic window than currently approved therapies. Continue reading